Tirzepatide
- Generic Name
- Tirzepatide
- Brand Names
- Mounjaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2023788-19-2
- Unique Ingredient Identifier
- OYN3CCI6QE
- Background
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclini...
- Indication
Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa
- Conditions
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-03-08
- Target Recruit Count
- 20
- Registration Number
- NCT06301256
A Study of LY3841136 in Japanese Participants With Obesity or Overweight
- Conditions
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 70
- Registration Number
- NCT06297616
- Locations
- 🇯🇵
Sumida Hospital, Sumida-ku, Tokyo, Japan
🇯🇵Hakata Clinic, Fukuoka, Japan
🇯🇵P-One Clinic, Hachioji, Tokyo, Japan
Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
- Conditions
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-10-09
- Target Recruit Count
- 730
- Registration Number
- NCT06246799
- Locations
- 🇺🇸
University Health System Texas Diabetic Institute, San Antonio, Texas, United States
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1000
- Registration Number
- NCT06221969
- Locations
- 🇺🇸
Univ of Alabama_Birmingham, Birmingham, Alabama, United States
🇺🇸Prime Medical Group, LLC, Gilbert, Arizona, United States
🇺🇸Velocity Clinical Research-Phoenix, Phoenix, Arizona, United States
Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- University of Melbourne
- Target Recruit Count
- 352
- Registration Number
- NCT06191848
- Locations
- 🇦🇺
St Vincents Hospital Melbourne, Fitzroy, Victoria, Australia
Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity
- Conditions
- Interventions
- First Posted Date
- 2023-12-22
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Royal North Shore Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06180616
GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Feasibility Trial
- Conditions
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT06162715
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Conditions
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1040
- Registration Number
- NCT06143956
- Locations
- 🇺🇸
Pacific Diabetes & Endocrine Center, Honolulu, Hawaii, United States
🇺🇸Medical Research Partners, Ammon, Idaho, United States
🇺🇸Great Lakes Clinical Trials - Andersonville, Chicago, Illinois, United States
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
- Conditions
- Interventions
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 800
- Registration Number
- NCT06131437
- Locations
- 🇺🇸
Univ of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸Chambliss Clinical Trials LLC, Montgomery, Alabama, United States
🇺🇸FDRC, Costa Mesa, California, United States
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 150
- Registration Number
- NCT06075667
- Locations
- 🇺🇸
Barry J. Reiner, MD, LLC, Baltimore, Maryland, United States
🇺🇸Vanderbilt Health One Hundred Oaks, Nashville, Tennessee, United States
🇺🇸M Health Fairview - Delaware Clinical Research Unit (DCRU), Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.